Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 4/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | P4HB | P07237 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | UNG | P13051 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30798937 | 1.00 | PTGS2 (0.61) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL1234979 | 1.00 | PTGS2 (0.61) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL4732774 | 0.89 | PTGS2 (0.73) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL4427602 | 0.88 | TTR (0.69) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL4427604 | 0.88 | TTR (0.69) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL4895017 | 0.87 | TTR (0.57) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL6171618 | 0.87 | TTR (0.57) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL6171623 | 0.87 | TTR (0.57) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL4895007 | 0.87 | TTR (0.57) | PTGS2TTRDPP4CA12CA1 | |
| SCHEMBL6173129 | 0.86 | P4HB (0.60) | PTGS2TTRDPP4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113582911-B | Multi-target donepezil-hydroxamic acid compound, and preparation method and application thereof | 山东大学 | 2024-03-12 | — | — | CN | disclosed |
| CN-113582911-A | Multi-target donepezil-hydroxamic acid type compound and preparation method and application thereof | 山东大学 | 2021-11-02 | — | — | CN | disclosed |
| US-10059657-B2 | Class-and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-08-28 | — | — | US | disclosed |
| US-20170267630-A1 | CLASS-AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267630-A1 | CLASS-AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267630-A1 | CLASS-AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-9540317-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540317-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2202223-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202223-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-7709519-B2 | Benzimidazolylidene propane-1,3 dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1752452-A9 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1752452-A1 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-14 | — | — | EP | disclosed |
| EP-1192127-B1 | SUBSTITUTED BENZAMIDE INHIBITORS OF RHINOVIRUS 3C PROTEASE | AGOURON PHARMA (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6369226-B1 | ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1192127-A1 | SUBSTITUTED BENZAMIDE INHIBITORS OF RHINOVIRUS 3C PROTEASE | Agouron Pharmaceuticals, Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000078708-A1 | SUBSTITUTED BENZAMIDE INHIBITORS OF RHINOVIRUS 3C PROTEASE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GPER1, GNRHR, AR | PTGS2 508/4885TTR 4460/4885DPP4 1097/4885 |
| US-20170267630-A1 | CLASS-AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | PTGS2 3250/4885TTR 4682/4885DPP4 2528/4885 |
| US-10059657-B2 | Class-and isoform-specific HDAC inhibitors and uses thereof | HDAC1, HDAC5, HDAC6 | PTGS2 3250/4885TTR 4682/4885DPP4 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.